|View printer-friendly version|
|April 12, 2006 1:36 p.m.|
|Teva Announces Approval of Mitoxantrone Hydrochloride Injection USP|
Jerusalem, Israel, April 12, 2006 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has granted final approval for the Company's ANDA for Mitoxantrone Hydrochloride Injection USP, 2 mg/mL. Shipment of this product will begin immediately.